Current status of the taxanes as adjuvant therapy for breast cancer Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Breast Neoplasms
  • Taxoids

abstract

  • Adjuvant chemotherapy for breast cancer reduces the risks of recurrence and death in many subsets of patients. The quest for better regimens, defined as both more effective and less toxic has led to numerous clinical trials testing the taxanes in the adjuvant setting. These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research.

publication date

  • November 6, 2007

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.breast.2007.07.022

PubMed ID

  • 17723302

Additional Document Info

start page

  • S132

end page

  • 5

volume

  • 16

number

  • 2 SUPPL.